CA2534791C - Ecorces de levures pour le traitement ou la prevention de l'hyperglycemie ou pour la stabilisation de la glycemie - Google Patents
Ecorces de levures pour le traitement ou la prevention de l'hyperglycemie ou pour la stabilisation de la glycemie Download PDFInfo
- Publication number
- CA2534791C CA2534791C CA2534791A CA2534791A CA2534791C CA 2534791 C CA2534791 C CA 2534791C CA 2534791 A CA2534791 A CA 2534791A CA 2534791 A CA2534791 A CA 2534791A CA 2534791 C CA2534791 C CA 2534791C
- Authority
- CA
- Canada
- Prior art keywords
- yeast
- hyperglycemia
- preparation
- content
- yeast walls
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 201000001421 hyperglycemia Diseases 0.000 title claims abstract description 57
- 238000011282 treatment Methods 0.000 title claims abstract description 33
- 230000002265 prevention Effects 0.000 title claims abstract description 26
- 230000006641 stabilisation Effects 0.000 title claims abstract description 25
- 210000005253 yeast cell Anatomy 0.000 title description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 96
- 238000002360 preparation method Methods 0.000 claims abstract description 53
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 14
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 91
- 239000003795 chemical substances by application Substances 0.000 claims description 49
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 44
- 239000008103 glucose Substances 0.000 claims description 43
- 239000008280 blood Substances 0.000 claims description 35
- 210000004369 blood Anatomy 0.000 claims description 35
- 238000011105 stabilization Methods 0.000 claims description 23
- 229920002527 Glycogen Polymers 0.000 claims description 22
- 229940096919 glycogen Drugs 0.000 claims description 22
- 229920000057 Mannan Polymers 0.000 claims description 20
- 229920001503 Glucan Polymers 0.000 claims description 18
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 claims description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 210000002421 cell wall Anatomy 0.000 abstract description 3
- 238000000034 method Methods 0.000 description 22
- 208000035404 Autolysis Diseases 0.000 description 8
- 206010057248 Cell death Diseases 0.000 description 7
- 230000028043 self proteolysis Effects 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 5
- 230000007071 enzymatic hydrolysis Effects 0.000 description 5
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 102100024023 Histone PARylation factor 1 Human genes 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 235000013405 beer Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 108010005335 mannoproteins Proteins 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004186 food analysis Methods 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03018222.4 | 2003-08-11 | ||
| EP03018222 | 2003-08-11 | ||
| EP03020253.5 | 2003-09-08 | ||
| EP03020253 | 2003-09-08 | ||
| PCT/EP2004/008933 WO2005021015A1 (fr) | 2003-08-11 | 2004-08-10 | Ecorces de levures pour le traitement ou la prevention de l’hyperglycemie ou pour la stabilisation de la glycemie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2534791A1 CA2534791A1 (fr) | 2005-03-10 |
| CA2534791C true CA2534791C (fr) | 2014-10-28 |
Family
ID=34276722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2534791A Expired - Fee Related CA2534791C (fr) | 2003-08-11 | 2004-08-10 | Ecorces de levures pour le traitement ou la prevention de l'hyperglycemie ou pour la stabilisation de la glycemie |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7459159B2 (enExample) |
| EP (1) | EP1663266B1 (enExample) |
| JP (2) | JP4808619B2 (enExample) |
| KR (1) | KR101076209B1 (enExample) |
| AU (1) | AU2004267928B2 (enExample) |
| BR (1) | BRPI0413481A (enExample) |
| CA (1) | CA2534791C (enExample) |
| DK (1) | DK1663266T3 (enExample) |
| EA (1) | EA009677B1 (enExample) |
| ES (1) | ES2405934T3 (enExample) |
| MA (1) | MA28072A1 (enExample) |
| MX (1) | MXPA06001741A (enExample) |
| NO (1) | NO20061138L (enExample) |
| NZ (1) | NZ545594A (enExample) |
| PL (1) | PL1663266T3 (enExample) |
| PT (1) | PT1663266E (enExample) |
| WO (1) | WO2005021015A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006117566A (ja) * | 2004-10-20 | 2006-05-11 | Asahi Breweries Ltd | 糖代謝改善剤 |
| JP2007195444A (ja) * | 2006-01-26 | 2007-08-09 | Asahi Food & Healthcare Ltd | ダイエット飲食品 |
| CN101528245A (zh) * | 2006-08-24 | 2009-09-09 | 麒麟控股株式会社 | 用于改善皮肤状态的组合物 |
| JP5238166B2 (ja) * | 2007-02-02 | 2013-07-17 | 株式会社ヤクルト本社 | インターロイキン１２産生抑制剤 |
| FR2919187B1 (fr) * | 2007-07-25 | 2009-11-27 | Lesaffre & Cie | Utilisation d'ecorces de levure pour le traitement et/ou la prevention de l'hyperinsulinemie. |
| FR2949064B1 (fr) * | 2009-08-14 | 2011-10-07 | Lesaffre & Cie | Nouvelles compositions destinees a la prevention et/ou au traitement du diabete |
| FR2978967B1 (fr) * | 2011-08-09 | 2020-03-20 | Lesaffre Et Compagnie | Ecorces de levure enrichies en vitamine d2, compositions les contenant, leur procede de preparation, leurs utilisations et dispositif permettant la mise en oeuvre du procede |
| MD4216C1 (ro) * | 2012-08-15 | 2013-11-30 | Институт Микробиологии И Биотехнологии Академии Наук Молдовы | Tulpină de drojdii Saccharomyces cerevisiae - producătoare de manani |
| WO2017179691A1 (ja) * | 2016-04-14 | 2017-10-19 | テーブルマーク株式会社 | 血糖値低下用又はｇｉ値低減用の食品組成物又は組み合わせ |
| JPWO2017199951A1 (ja) * | 2016-05-17 | 2019-03-14 | 興人ライフサイエンス株式会社 | 糖尿病予防効果を有する酵母エキス |
| IT201600069379A1 (it) * | 2016-07-04 | 2018-01-04 | Prosol S P A | Composizione sostanzialmente costituita da pareti cellulari di lievito e procedimento per la sua preparazione |
| PL3685681T3 (pl) | 2019-01-23 | 2024-10-21 | Lesaffre Et Compagnie | Produkt drożdżowy i zawierająca go kompozycja do zastosowania jako środek prebiotyczny |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5774072A (en) * | 1980-10-29 | 1982-05-10 | Yamanouchi Pharmaceut Co Ltd | Granule of dietary fiber and its preparation |
| US4992540A (en) * | 1984-11-28 | 1991-02-12 | Massachusetts Institute Of Technology | Glucan composition and process for preparation thereof |
| JPS61167622A (ja) * | 1985-01-22 | 1986-07-29 | Asahi Breweries Ltd | 糖尿病コントロ−ル剤 |
| US4962094A (en) * | 1988-10-28 | 1990-10-09 | Alpha Beta Technology, Inc. | Glucan dietary additives |
| JP3647042B2 (ja) * | 1993-12-28 | 2005-05-11 | ソシエテ デ プロデユイ ネツスル ソシエテ アノニム | 可溶性繊維に富むシリアル食品 |
| DE4413023A1 (de) * | 1994-04-18 | 1995-10-19 | Hoechst Ag | Verfahren zur Gewinnung eines Faktors mit insulinartiger Wirkung aus Hefeextrakt |
| AUPN166195A0 (en) * | 1995-03-13 | 1995-04-06 | Norvet Research Pty Limited | Process for glucan extraction |
| AUPN398295A0 (en) * | 1995-07-05 | 1995-07-27 | Carlton And United Breweries Limited | Chemical compounds and processes for their production |
| US5773426A (en) * | 1996-06-07 | 1998-06-30 | Masaki Shirota | Proteoglucan and antidiabetic drug thereof |
| JP4441740B2 (ja) * | 1996-09-25 | 2010-03-31 | グレースリンク リミテッド | β−グルカン製品および穀類からの抽出方法 |
| DE19835767A1 (de) * | 1998-08-07 | 2000-02-17 | Kulicke Werner Michael | Verfahren zur Gewinnung hochmolekularer biologisch aktiver immunmodulierender Polysaccharide aus Hefe Saccharomyces Cerevisiae |
| FR2800076B1 (fr) * | 1999-10-22 | 2003-11-14 | Lesaffre & Cie | Mannoproteines solubles |
| AU2001282708B2 (en) * | 2000-07-03 | 2007-01-04 | Granate Seed Limited | Cold water soluble beta-glucan product and process for preparing the same |
| KR20090057480A (ko) * | 2001-04-27 | 2009-06-05 | 아지노모토 가부시키가이샤 | 면역강화제 |
| FR2825004B1 (fr) * | 2001-05-22 | 2005-02-11 | Bio Springer | Produit dietetique satiant |
| WO2002098440A1 (en) * | 2001-06-01 | 2002-12-12 | Ajinomoto Co., Inc. | Drugs for diabetes |
| US20030118989A1 (en) * | 2001-12-21 | 2003-06-26 | Carsten Rosenow | Differential isolation of cellular content for biological assays |
-
2004
- 2004-08-10 DK DK04763951.3T patent/DK1663266T3/da active
- 2004-08-10 EA EA200600402A patent/EA009677B1/ru not_active IP Right Cessation
- 2004-08-10 WO PCT/EP2004/008933 patent/WO2005021015A1/fr not_active Ceased
- 2004-08-10 AU AU2004267928A patent/AU2004267928B2/en not_active Ceased
- 2004-08-10 EP EP04763951A patent/EP1663266B1/fr not_active Expired - Lifetime
- 2004-08-10 PT PT47639513T patent/PT1663266E/pt unknown
- 2004-08-10 BR BRPI0413481-8A patent/BRPI0413481A/pt not_active IP Right Cessation
- 2004-08-10 KR KR1020067002769A patent/KR101076209B1/ko not_active Expired - Fee Related
- 2004-08-10 US US10/567,621 patent/US7459159B2/en not_active Expired - Fee Related
- 2004-08-10 PL PL04763951T patent/PL1663266T3/pl unknown
- 2004-08-10 CA CA2534791A patent/CA2534791C/fr not_active Expired - Fee Related
- 2004-08-10 JP JP2006522971A patent/JP4808619B2/ja not_active Expired - Fee Related
- 2004-08-10 NZ NZ545594A patent/NZ545594A/en not_active IP Right Cessation
- 2004-08-10 ES ES04763951T patent/ES2405934T3/es not_active Expired - Lifetime
- 2004-08-10 MX MXPA06001741A patent/MXPA06001741A/es active IP Right Grant
-
2006
- 2006-02-08 MA MA28784A patent/MA28072A1/fr unknown
- 2006-03-09 NO NO20061138A patent/NO20061138L/no not_active Application Discontinuation
-
2007
- 2007-12-17 US US12/002,360 patent/US20090022758A1/en not_active Abandoned
-
2011
- 2011-04-13 JP JP2011089381A patent/JP2011178794A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ES2405934T3 (es) | 2013-06-04 |
| PT1663266E (pt) | 2013-04-30 |
| MXPA06001741A (es) | 2006-05-12 |
| AU2004267928A1 (en) | 2005-03-10 |
| US20090022758A1 (en) | 2009-01-22 |
| AU2004267928B2 (en) | 2010-10-21 |
| EA009677B1 (ru) | 2008-02-28 |
| DK1663266T3 (da) | 2013-05-13 |
| NZ545594A (en) | 2009-09-25 |
| EA200600402A1 (ru) | 2006-08-25 |
| WO2005021015A1 (fr) | 2005-03-10 |
| JP4808619B2 (ja) | 2011-11-02 |
| EP1663266A1 (fr) | 2006-06-07 |
| JP2011178794A (ja) | 2011-09-15 |
| PL1663266T3 (pl) | 2013-07-31 |
| NO20061138L (no) | 2006-05-10 |
| US7459159B2 (en) | 2008-12-02 |
| KR20060037432A (ko) | 2006-05-03 |
| MA28072A1 (fr) | 2006-08-01 |
| US20060257422A1 (en) | 2006-11-16 |
| BRPI0413481A (pt) | 2006-10-17 |
| CA2534791A1 (fr) | 2005-03-10 |
| JP2007501829A (ja) | 2007-02-01 |
| KR101076209B1 (ko) | 2011-10-24 |
| EP1663266B1 (fr) | 2013-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090022758A1 (en) | Yeast cell walls for the treatment or prevention of hyperglycemia or for the stabilization of glycemia | |
| EP2170359B1 (fr) | Utilisation d'écorces de levure pour le traitement et / ou la prévention de l'hyperinsulinémie | |
| EP3426277A1 (fr) | Extrait de safran pour le traitement des troubles du sommeil | |
| CN100377719C (zh) | 用于治疗或预防高血糖症或用于稳定血糖的酵母细胞壁 | |
| JP7411938B2 (ja) | 酵素分解核酸による毛細血管新生剤及び毛細血管を新生する方法 | |
| FR2492662A1 (fr) | Composition pharmaceutique contenant de la d-biotine pour le traitement du diabete sucre | |
| FR3141617A1 (fr) | Composition pour son utilisation dans le traitement d’un syndrome de l'intestin irritable et/ou dans le traitement d’une hyperperméabilité intestinale. | |
| EP4558155A1 (fr) | Beta-extrait de parois cellulaires de levure saccharomyces cerevisiae riche en glucanes dans la prévention ou le traitement d'une maladie associée ou causée par une infection à lawsonia intraceiiuiaris | |
| FR3162342A1 (fr) | Produits alimentaires, notamment produits de boulangerie enrichis en gaba et benefiques pour la sante | |
| WO2022195212A1 (fr) | Inhibiteurs glycosidiques de levure | |
| WO2011018580A1 (fr) | Compositions a base de chrome et de beta-glucanes de levure destinees a la prevention et/ou au traitement du diabete |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20220301 |
|
| MKLA | Lapsed |
Effective date: 20200831 |